DRF-1042
Antineoplastic Agent; structure in first source
Also Known As:
5-(2'-hydroxyethoxy)-20(S)-camptothecin; DRF1042
Networked: 3
relevant articles (0 outcomes,
2 trials/studies)
Bio-Agent Context: Research Results
Experts
1. | Katneni, Kasiram:
3 articles
(04/2005 - 09/2003)
|
2. | Mamidi, Rao N V S:
3 articles
(04/2005 - 09/2003)
|
3. | Srinivas, Nuggehally R:
3 articles
(04/2005 - 09/2003)
|
4. | Upreti, Vijay V:
3 articles
(04/2005 - 09/2003)
|
5. | Chatterjee, Arani:
2 articles
(04/2005 - 07/2004)
|
6. | Digumarti, Raghunadharao:
2 articles
(04/2005 - 07/2004)
|
7. | Jiwatani, Sangeeta:
2 articles
(04/2005 - 07/2004)
|
8. | Srinivas, Maddali L:
2 articles
(04/2005 - 07/2004)
|
9. | Surath, Anjna:
2 articles
(04/2005 - 07/2004)
|
10. | Uppalapati, Srihari:
2 articles
(04/2005 - 07/2004)
|
Related Diseases
1. | Neoplasms (Cancer)
09/01/2003
- " The method is simple, sensitive and reliable and has been successfully implemented to investigate the clinical pharmacokinetics of DRF-1042 in cancer patients in a phase I clinical trial." 07/01/2004
- " The objective of this study was to characterize the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetics, and antitumor effects of DRF-1042, a novel camptothecin analog, in refractory solid tumor patients. " 07/01/2004
- " Safety, tolerability, pharmacokinetics, and pharmacodynamics of an orally active novel camptothecin analog, DRF-1042, in refractory cancer patients in a phase I dose escalation study." 04/01/2005
- " The purpose of this bridging phase I study was to characterize the toxicity, pharmacokinetics, and antitumor effects of a capsule formulation of DRF-1042, a novel camptothecin analog, in refractory solid tumor patients. " 04/01/2005
- " Safety, tolerability, and pharmacokinetics of a capsule formulation of DRF-1042, a novel camptothecin analog, in refractory cancer patients in a bridging phase I study."
|
|
Related Drugs and Biologics